厄洛替尼靶向治疗联合化疗治疗非小细胞肺癌临床观察

摘要

目的 探讨厄洛替尼靶向治疗联合化学治疗(简称化疗)治疗非小细胞肺癌(NSCLC)的疗效及对患者免疫功能和生存质量的影响.方法 选取医院2015年3月至2017年3月收治的中晚期NSCLC患者104例,根据治疗方案的不同分为化疗组(GP方案化疗,n=64)和联合组(厄洛替尼靶向治疗联合GP方案化疗,n=40).结果 联合组患者总有效率及疾病控制率分别为72.50％和95.00％,明显高于化疗组患者的48.44％和81.25％(P0.05).结论 厄洛替尼靶向治疗联合化疗治疗NSCLC安全有效,且能明显提高患者免疫功能和生存质量.%Objective To investigate the clinical effect of erlotinib target therapy combine with chemotherapy for treating non-small cell lung cancer(NSCLC)and its effect on immune function and quality of life. Methods Totally 104 patients with advanced NSCLC admitted to our hospital from March 2015 to March 2017 were selected and divided into the chemotherapy group(GP chemotherapy,n=64)and the combination group (erlotinib target therapy combined with GP chemotherapy ,n =40 ) according to the different treatment regimens. Results The total effective rate and disease control rate of the combination group were 72. 50％ and 95. 00％,which were significantly higher than 48. 44％ and 81. 25％ of the chemotherapy group(P 0. 05). Conclusion Erlotinib target therapy combined with chemotherapy for treating NSCLC is safe and effective,it can significantly improve the patients′ immune function and quality of life.